Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY)

Idorsia Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Fabry Disease

Treatments: Drug: Placebo; Drug: Lucerastat

Study type: Interventional

Funder types: Industry

Identifiers

NCT03425539

ID-069A301

Details and patient eligibility

About

This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.

Full description

The primary objective of this prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily collection of patient-reported outcomes with an electronic diary.

Enrollment: 118 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Signed and dated ICF prior to any study-mandated procedure;

2. Male or female adult subjects;

3. FD diagnosis confirmed with local genetic test results;

4. Fabry-associated neuropathic pain, as defined by the subject, in the last 3 months prior to screening;

5. Enzyme replacement therapy (ERT) status:

   1. Subject never treated with ERT; or
   2. Subject has not received ERT for at least 6 months prior to screening; or
   3. Subject treated with ERT since at least 12 months at the time of the screening visit, and agreeing to stop ERT for approximately 8 months.

6. A woman of childbearing potential is eligible only under certain conditions, e.g. taking contraceptive measures.

7. Subjects with moderate or severe neuropathic pain during the screening period.

Exclusion criteria

1. Pregnant, planning to be become pregnant, or lactating subject.
2. Severe renal insufficiency (eGFR < 30 mL/min/1.73 m2) at screening.
3. Subject on regular dialysis for the treatment of chronic kidney disease.
4. Known and documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within 6 months prior to screening.
5. Clinically significant unstable cardiac disease (e.g. uncontrolled symptomatic arrhythmia, congestive heart failure NYHA class III or IV).
6. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

118 participants in 2 patient groups, including a placebo group

Lucerastat

Experimental group

Treatment:

Drug: Lucerastat

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo